How do a patent foramen ovale (PFO) and an atrial septal defect (ASD) differ in anatomy, clinical significance, and treatment options?

PFO vs ASD: Key Anatomical, Clinical, and Treatment Differences

A patent foramen ovale (PFO) is a persistent flaplike communication where the septum primum overlaps the septum secundum at the fossa ovalis—a normal fetal structure that fails to seal—while an atrial septal defect (ASD) represents a true deficiency in atrial septal tissue with distinct anatomical subtypes and fundamentally different hemodynamic consequences.

Anatomical Distinctions

Patent Foramen Ovale

• Not a true defect: The PFO is a flaplike communication where septum primum covers the fossa ovalis and overlaps the superior limbic band of septum secundum 1
• Prevalence: Present in 25-30% of adults 2
• Normal embryology: Part of normal fetal development that typically closes after birth but persists in a substantial portion of the population 2

Atrial Septal Defect

True deficiency in atrial septal tissue with four distinct anatomical types 1, 3:

• Secundum ASD (75-80%): Located in the region of fossa ovalis
• Primum ASD (15-20%): Positioned inferiorly near the crux of the heart, part of atrioventricular septal defect spectrum
• Sinus venosus defect (5-10%): Located superiorly near superior vena cava or inferiorly near inferior vena cava
• Coronary sinus defect (<1%): Defect in roof of coronary sinus

Critical anatomical associations 1:

• Primum ASD: Nearly always accompanied by cleft in anterior mitral valve leaflet
• Sinus venosus defects: Frequently have partial anomalous pulmonary venous drainage (right pulmonary veins)
• Overall: Associated with additional malformations in nearly 30% of cases

Clinical Significance and Natural History

PFO: Paradoxical Embolism Pathway

• Primary risk: Paradoxical embolism leading to cryptogenic stroke 2
• Mechanism: Right-to-left shunting allows venous emboli to bypass pulmonary filtration
• No hemodynamic overload: Does not cause right heart volume overload or pulmonary hypertension in isolation
• Associated conditions: Decompression sickness, systemic deoxygenation syndromes 4

ASD: Volume Overload Syndrome

Hemodynamic consequences 1, 3:

• Right ventricular volume overload from left-to-right shunting
• Pulmonary overcirculation with Qp:Qs typically ≥1.5 when hemodynamically significant
• Progressive complications:
  • Atrial arrhythmias (atrial flutter, atrial fibrillation, sick sinus syndrome)
  • Right heart failure
  • Pulmonary arterial hypertension (develops later than with VSD or PDA)
  • Paradoxical embolism (less common than with PFO)

Natural history without closure 3:

• Reduced functional capacity
• Progressive arrhythmias
• Increased mortality compared to age-matched population
• Optimal closure timing: Before age 15-25 years for best survival outcomes

Treatment Algorithms

PFO Management: Cryptogenic Stroke Context

For patients <60 years with PFO-related cryptogenic stroke after extensive workup 5:

When all options acceptable:

• Weak recommendation: PFO closure + antiplatelet therapy over anticoagulation

When anticoagulation contraindicated/declined:

• STRONG RECOMMENDATION: PFO closure + antiplatelet therapy over antiplatelet therapy alone 5
• High-quality evidence for stroke reduction
• Procedure <2 hours, 1-day hospital stay, full recovery within weeks

When closure contraindicated/declined:

• Weak recommendation: Anticoagulation over antiplatelet therapy alone

Key limitations 5:

• Applicability uncertain in patients >60 years (fewer cryptogenic strokes from paradoxical emboli)
• Uncertain benefit with traditional cerebrovascular risk factors (diabetes, hypertension, hyperlipidemia)

ASD Management: Hemodynamic-Driven Approach

Indications for closure 3:

Absolute criteria:

1. Hemodynamically significant shunt (RV enlargement and/or Qp:Qs ≥1.5)
2. Absence of irreversible pulmonary vascular disease
3. Symptoms (functional decline, arrhythmias, heart failure) OR asymptomatic with significant shunt

Assessment requirements:

• Evaluate pulmonary pressures, vascular resistance, shunt ratio
• Exclude irreversible pulmonary vascular disease

Expected outcomes with closure 3:

• Improved functional capacity
• Favorable RV remodeling
• Reduction in arrhythmias
• Benefits even in patients >40 years (though optimal closure before age 15-25)

Device selection considerations 6:

• Secundum ASD: Standard closure devices effective
• Coexisting PFO + small ASD: Requires careful device selection to prevent residual shunting
• GORE® CARDIOFORM devices associated with better anatomical closure in complex anatomy

Critical Pitfalls

Misdiagnosis risk 7, 8:

• PFO and ASD require careful distinction despite both being interatrial communications
• Different embryological origins demand different management strategies
• Comprehensive imaging (TTE, TEE, cardiac MRI, intracardiac echo) essential for accurate characterization

PFO closure complications 5:

• Device-related adverse events
• Persistent atrial fibrillation
• Procedure/device-related events must be weighed against stroke reduction benefit

ASD-specific concerns 9:

• Patients with PFO or ASD undergoing pulmonary vein isolation for atrial fibrillation have worse outcomes
• Higher rates of hospitalization (HR 1.14), cardioversion (HR 1.18), AAD use (HR 1.12), and stroke (HR 1.36)
• Chronic atrial stretch and remodeling increase AF recurrence

Age considerations:

• PFO closure benefits uncertain >60 years 5
• ASD closure beneficial even >40 years but optimal before age 15-25 3